ESMO Immuno-Oncology Congress 2022

Back to basics: do we need more immuno-oncology in the core curriculum?
Due to the current widespread use of immunotherapies and their increasing complexities, further immune-oncology education is needed in medical schools and beyond

Is there still a future for cancer vaccines?
Despite generally disappointing clinical trial results, technological innovations mean that realising the potential for cancer vaccines could be just around the corner

Is combining radiotherapy and immunotherapy a viable treatment option?
Conflicting clinical results on the benefits of combined radiotherapy and immunotherapy may derive from differences in treatment sequencing

Nina Bhardwaj receives the ESMO Immuno-Oncology Award 2022
According to the 2022 awardee, the future of immuno-oncology lies in the modulation of the tumour microenvironment and cancer vaccines